Weight-loss drugs’ challenge to pharma’s safety infrastructure
For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity… Read More
For the huge commercial success represented by GLP-1 agonists such as Mounjaro and Ozempic, particularly now in the context of treating obesity… Read More
Novo Nordisk has received a Warning Letter from the US Food and Drug Administration (FDA) related to violations of postmarketing adverse drug experience (PADE) regulations. The letter relates to an inspection that took place in early 2025, in which the FDA found serious violations of PADE reporting… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More
News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW. This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More
An estimated 1.6 million adults in England, Wales and Scotland used weight loss drugs in the past year, new findings suggest. The study, led by researchers at University College London, showed 1.6 million adults used drugs including Wegovy and Mounjaro to help lose weight between early 2024 and early 2025. Read More
A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing appetite and reducing body weight. Notably, testing in animals also showed that it worked without some of Ozempic’s side effects such as nausea, constipation and significant loss of muscle… Read More